Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Inclusion Criteria: * Pathological diagnosis of either squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction. * Clinical stage IIA, IIB or III without metastatic disease * Patients must have documented EGFR status or have tumor tissue available for assessment of EGFR status by IHC * Patients must be surgical candidates as determined by surgical consult. * Patients must agree to surgery. * ECOG performance status 0 or 2 * Absolute neutrophil count (ANC) \> 1,000 mm3 * Platelet count \> 75,000 mm3· Hemoglobin \> 10g/dL * Bilirubin \< 2.5 X upper limit of normal * AST (SGOT) or ALT (SGPT) \< 5.0 ´ upper limit of normal * Creatinine \< 2.0 X upper limit of normal Exclusion Criteria: * No history of or current brain metastasis. * No significant history of uncontrolled cardiac disease; i.e. uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction. * No history of interstitial pneumonitis or pulmonary fibrosis, or suspicion of interstitial pneumonitis or pulmonary fibrosis on imaging. * No concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s). * No prior use of radiation or chemotherapy for cancer of the esophagus or GE junction * No prior therapy that specifically and directly targets the EGFR pathway (such as kinase inhibitors and antibodies directed against the HER family receptors). * No prior severe infusion reaction to a monoclonal antibody. * No major surgery within 28 days prior to being registered for protocol therapy. * No clinically significant infections as judged by the treating investigator. * No acute hepatitis or known HIV. * No other active malignancies. * Negative pregnancy test. * No female patients currently breastfeeding.